Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PONENTE: Benralizumab OCS reduction in severe eosinophilic asthma
NCT03557307Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of benralizumab in severe eosinophilic asthma (SEA), sponsored by AstraZeneca. Started Aug 2018; status: completed.
02
Drugs
benralizumab
03
Conditions
severe eosinophilic asthma (SEA)
Beyond the preview
Go deeper on NCT03557307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557307.